The impact of combined contraceptive vaginal ring on vaginal environment: an observational, longitudinal study
CONCLUSIONS: Our results suggest that CVR does not adversely affect the composition and structure of the vaginal microbiome. However, special care should be taken in patients with a history of vestibulodynia and/or recurrent vulvovaginal infections.PMID:37417287 | DOI:10.1080/13625187.2023.2228440 (Source: The European Journal of Contraception and Reproductive Health Care)
Source: The European Journal of Contraception and Reproductive Health Care - July 7, 2023 Category: Reproduction Medicine Authors: Filippo Murina Alessandra Graziottin Stefania Di Francesco Dario Recalcati Source Type: research
Venous Thromboembolism Requiring Anticoagulation Following Knee Arthroscopy in a Young Woman With an Intravaginal Contraceptive Device
Orthopedics. 2021 Sep-Oct;44(5):e687-e690. doi: 10.3928/01477447-20210818-02. Epub 2021 Sep 1.ABSTRACTVenous thromboembolism following elective knee arthroscopy remains relatively rare. NuvaRing (Merck & Co), an intravaginal contraceptive device, has received attention recently due to reports detailing unexpected catastrophic pulmonary embolism and further suggesting an increased risk of venous and arterial thrombotic events in women who use it. A healthy, 30-year-old woman with a NuvaRing contraceptive device presented to the sports medicine clinic with knee pain, swelling, and mechanical symptoms. She was diagnosed w...
Source: Orthopedics - September 30, 2021 Category: Orthopaedics Authors: Robert L Parisien Erik S Henkelman Ronald E McCartney Robert Nicoletta Source Type: research
Venous Thromboembolism Requiring Anticoagulation Following Knee Arthroscopy in a Young Woman With an Intravaginal Contraceptive Device
Orthopedics. 2021 Sep-Oct;44(5):e687-e690. doi: 10.3928/01477447-20210818-02. Epub 2021 Sep 1.ABSTRACTVenous thromboembolism following elective knee arthroscopy remains relatively rare. NuvaRing (Merck & Co), an intravaginal contraceptive device, has received attention recently due to reports detailing unexpected catastrophic pulmonary embolism and further suggesting an increased risk of venous and arterial thrombotic events in women who use it. A healthy, 30-year-old woman with a NuvaRing contraceptive device presented to the sports medicine clinic with knee pain, swelling, and mechanical symptoms. She was diagnosed w...
Source: Orthopedics - September 30, 2021 Category: Orthopaedics Authors: Robert L Parisien Erik S Henkelman Ronald E McCartney Robert Nicoletta Source Type: research
Venous Thromboembolism Requiring Anticoagulation Following Knee Arthroscopy in a Young Woman With an Intravaginal Contraceptive Device
Orthopedics. 2021 Sep-Oct;44(5):e687-e690. doi: 10.3928/01477447-20210818-02. Epub 2021 Sep 1.ABSTRACTVenous thromboembolism following elective knee arthroscopy remains relatively rare. NuvaRing (Merck & Co), an intravaginal contraceptive device, has received attention recently due to reports detailing unexpected catastrophic pulmonary embolism and further suggesting an increased risk of venous and arterial thrombotic events in women who use it. A healthy, 30-year-old woman with a NuvaRing contraceptive device presented to the sports medicine clinic with knee pain, swelling, and mechanical symptoms. She was diagnosed w...
Source: Orthopedics - September 30, 2021 Category: Orthopaedics Authors: Robert L Parisien Erik S Henkelman Ronald E McCartney Robert Nicoletta Source Type: research
Venous Thromboembolism Requiring Anticoagulation Following Knee Arthroscopy in a Young Woman With an Intravaginal Contraceptive Device
Orthopedics. 2021 Sep-Oct;44(5):e687-e690. doi: 10.3928/01477447-20210818-02. Epub 2021 Sep 1.ABSTRACTVenous thromboembolism following elective knee arthroscopy remains relatively rare. NuvaRing (Merck & Co), an intravaginal contraceptive device, has received attention recently due to reports detailing unexpected catastrophic pulmonary embolism and further suggesting an increased risk of venous and arterial thrombotic events in women who use it. A healthy, 30-year-old woman with a NuvaRing contraceptive device presented to the sports medicine clinic with knee pain, swelling, and mechanical symptoms. She was diagnosed w...
Source: Orthopedics - September 30, 2021 Category: Orthopaedics Authors: Robert L Parisien Erik S Henkelman Ronald E McCartney Robert Nicoletta Source Type: research
Venous Thromboembolism Requiring Anticoagulation Following Knee Arthroscopy in a Young Woman With an Intravaginal Contraceptive Device
Orthopedics. 2021 Sep-Oct;44(5):e687-e690. doi: 10.3928/01477447-20210818-02. Epub 2021 Sep 1.ABSTRACTVenous thromboembolism following elective knee arthroscopy remains relatively rare. NuvaRing (Merck & Co), an intravaginal contraceptive device, has received attention recently due to reports detailing unexpected catastrophic pulmonary embolism and further suggesting an increased risk of venous and arterial thrombotic events in women who use it. A healthy, 30-year-old woman with a NuvaRing contraceptive device presented to the sports medicine clinic with knee pain, swelling, and mechanical symptoms. She was diagnosed w...
Source: Orthopedics - September 30, 2021 Category: Orthopaedics Authors: Robert L Parisien Erik S Henkelman Ronald E McCartney Robert Nicoletta Source Type: research
Risk of sexual dysfunction with progestin-based contraceptives in women of child-bearing age
ConclusionOur study found an increase in the use of levonorgestrel (COC and IUD), drospirenone, and medroxyprogesterone in subjects with SD. The risk of contraceptives did not differ when compared with oral levonorgestrel. The small association size and lack of difference between drug formulations suggest a minimal impact of progestin-based contraceptives on sexual dysfunction. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - January 1, 2021 Category: Drugs & Pharmacology Source Type: research
Phexxi - A Nonhormonal Contraceptive Gel
Date: August 24, 2020
Issue #:
1605Summary:
The FDA has approvedPhexxi (Evofem), a
nonhormonal prescription-only vaginal gel containing
lactic acid, citric acid, and potassium bitartrate, for
prevention of pregnancy. The gel is intended for on-demand
contraception; it is not effective when used
after intercourse. It was previously approved for
use as a vaginal lubricant(Amphora), but was never
marketed. (Source: The Medical Letter)
Source: The Medical Letter - July 21, 2020 Category: Drugs & Pharmacology Authors: admin Tags: Annovera cervical cap Condom Contraceptives Depo-Provera Diaphragm EluRyng Flexi-T IUD Kyleena Levonorgestrel Liberte Liletta Medroxyprogesterone Mirena Mona Lisa Nexplanon NuvaRing Oral contraceptives ParaGard Phex Source Type: research
Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives
Conclusion
CYP2B6 slow metabolizer genotype worsens the pharmacokinetic interaction of efavirenz with hormonal contraceptives administered by vaginal ring. Efavirenz dose reduction in CYP2B6 slow metabolizers may reduce, but will likely not eliminate, this interaction. (Source: Pharmacogenetics and Genomics)
Source: Pharmacogenetics and Genomics - March 7, 2020 Category: Genetics & Stem Cells Tags: Original Articles Source Type: research
Surface roughness of different contraceptive vaginal rings: evaluation by scanning electron microscope (SEM).
Conclusion: The different composition of the vaginal rings' EVA membrane is not associated with different surface roughness. Ornibel is equivalent to NuvaRing in terms of surface roughness, despite the different composition of the membrane polymers.
PMID: 31922428 [PubMed - as supplied by publisher] (Source: The European Journal of Contraception and Reproductive Health Care)
Source: The European Journal of Contraception and Reproductive Health Care - January 9, 2020 Category: Reproduction Medicine Authors: Grandi G, Timò A, Sammarini M, Del Savio MC, Facchinetti F Tags: Eur J Contracept Reprod Health Care Source Type: research
Annovera - A New Contraceptive Vaginal Ring
Date: December 16, 2019
Issue #:
1587Summary: Annovera (TherapeuticsMD), a contraceptive vaginal
ring that releases segesterone acetate, a synthetic
progestin, and ethinyl estradiol, was approved by the
FDA in 2018 and is now available. It is the first product
to contain segesterone and the second vaginal ring
to become available in the US;NuvaRing, which
delivers etonogestrel and ethinyl estradiol, was the
first. UnlikeNuvaRing, which requires use of a new
ring each month, theAnnovera ring can be used for
an entire year, but it must be removed for one week
each month. (Source: The Medical Letter)
Source: The Medical Letter - December 9, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Annovera Contraceptives Estrogens etonogestrel IUD Nexplanon NuvaRing ombitasvir paritaprevir Progestins Ritonavir segesterone Technivie Viekira Pak Source Type: research
In vitro evaluation of microbial adhesion to a contraceptive vaginal ring with a new polymer composition.
CONCLUSION: The study demonstrates that the adherence of C. albicans, as well as that of L. acidophilus when co-cultured with C. albicans, is lower with the Ornibel vaginal ring compared with NuvaRing. These in vitro findings warrant future human trials using molecular techniques to assess the vaginal microbiota composition and to establish whether Ornibel can support vaginal health.
PMID: 30977415 [PubMed - as supplied by publisher] (Source: The European Journal of Contraception and Reproductive Health Care)
Source: The European Journal of Contraception and Reproductive Health Care - April 11, 2019 Category: Reproduction Medicine Authors: Sailer M, Colli E, Regidor PA Tags: Eur J Contracept Reprod Health Care Source Type: research
Application for the etonogestrel/ethinyl estradiol ring (after) — Potential for emergency contraception
Objectives: We aimed to describe the emergency contraceptive (EC) potential of the 11.7-mg etonogestrel/2.7-mg ethinyl estradiol contraceptive vaginal ring when placed at different time points in the follicular phase of the menstrual cycle. (Source: Contraception)
Source: Contraception - September 13, 2018 Category: OBGYN Authors: D Crabtree Sokol, M Natavio, B Nguyen, A Nelson, N Bender Source Type: research
Phase II dose-finding study on ovulation inhibition and cycle control associated with the use of contraceptive vaginal rings containing 17 β-estradiol and the progestagens etonogestrel or nomegestrol acetate compared to NuvaRing.
CONCLUSIONS: Contraceptive rings releasing 300 µg E2 and 75-125 µg/day of ENG or 500-900 µg/day of NOMAC provided adequate ovulation inhibition and cycle control and are generally well-tolerated. While non-inferiority to NuvaRing® was not met, among the investigational rings, the ENG-E2 125/300 ring provided the best cycle control.
PMID: 30203681 [PubMed - as supplied by publisher] (Source: The European Journal of Contraception and Reproductive Health Care)
Source: The European Journal of Contraception and Reproductive Health Care - September 11, 2018 Category: Reproduction Medicine Authors: Duijkers I, Klipping C, Heger-Mahn D, Fayad GN, Frenkl TL, Cruz SM, Korver T Tags: Eur J Contracept Reprod Health Care Source Type: research
Poster 441: Out With the Old, in with the Nuvaring ®. Pudendal Neuralgia: A Novel Complication of the Nuvaring®: Case Report
Roberta Lui: I Have No Relevant Financial Relationships To Disclose (Source: PM and R)
Source: PM and R - September 1, 2017 Category: Rehabilitation Authors: Roberta Lui, Anna M. Lasak Source Type: research
